Abstract
Background: Prevention of stroke is a pivotal intervention in the management of patients with atrial fibrillation (AF). Because of the difficulties of safely implementing Vitamin K Antagonists in all patients, there has been a growing interest in improving the pharmacological management of AF with newer antithrombotic agents. The new oral anticoagulants (NOACs) have been developed to overcome the limitations and improve the efficacy of the conventional oral anticoagulant drugs. Among the NOACs, apixaban - a very specific antagonist of activated factor Xa – has pharmacokinetic and pharmacodynamic properties that allow significant efficacy in AF management.
Objective: The aim of this review is to summarise the available data on the efficacy of apixaban in patients with AF, with a particular focus on the implications for its clinical management.
Results and Conclusion: Clinical application of apixaban in subgroups of patients with AF is still under investigation and some contraindications should be taken into account. Despite these limitations, apixaban is an effective alternative to warfarin and aspirin for stroke prevention in AF, with encouraging evidence also in terms of adherence to treatment.
Keywords: Apixaban, atrial fibrillation, new oral anticoagulants, stroke, major bleeding, Vitamin K antagonists.
Current Drug Targets
Title:New Advances in Atrial Fibrillation Management: The Role of Apixaban
Volume: 19 Issue: 6
Author(s): Giuseppe M.C. Rosano, Ilaria Spoletini, Walter Gianni and Cristiana Vitale*
Affiliation:
- Department of Medical Sciences, IRCCS San Raffaele Pisana, Rome,Italy
Keywords: Apixaban, atrial fibrillation, new oral anticoagulants, stroke, major bleeding, Vitamin K antagonists.
Abstract: Background: Prevention of stroke is a pivotal intervention in the management of patients with atrial fibrillation (AF). Because of the difficulties of safely implementing Vitamin K Antagonists in all patients, there has been a growing interest in improving the pharmacological management of AF with newer antithrombotic agents. The new oral anticoagulants (NOACs) have been developed to overcome the limitations and improve the efficacy of the conventional oral anticoagulant drugs. Among the NOACs, apixaban - a very specific antagonist of activated factor Xa – has pharmacokinetic and pharmacodynamic properties that allow significant efficacy in AF management.
Objective: The aim of this review is to summarise the available data on the efficacy of apixaban in patients with AF, with a particular focus on the implications for its clinical management.
Results and Conclusion: Clinical application of apixaban in subgroups of patients with AF is still under investigation and some contraindications should be taken into account. Despite these limitations, apixaban is an effective alternative to warfarin and aspirin for stroke prevention in AF, with encouraging evidence also in terms of adherence to treatment.
Export Options
About this article
Cite this article as:
Rosano M.C. Giuseppe, Spoletini Ilaria , Gianni Walter and Vitale Cristiana *, New Advances in Atrial Fibrillation Management: The Role of Apixaban, Current Drug Targets 2018; 19 (6) . https://dx.doi.org/10.2174/1389450118666171013095413
DOI https://dx.doi.org/10.2174/1389450118666171013095413 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
To Cardiovascular Disease and Beyond: New Therapeutic Perspectives of Statins in Autoimmune Diseases and Cancer
Current Drug Targets Family Psychoeducation in Clinical High Risk and First-Episode Psychosis
Adolescent Psychiatry Molecular Docking and Drug Discovery in β-Adrenergic Receptors
Current Medicinal Chemistry Safety of Systemic Biologic Agents in the Treatment of Non-malignant Skin Disorders
Current Drug Safety PCSK9 Inhibition in Atherosclerotic Cardiovascular Disease
Current Pharmaceutical Design NAD<sup>+</sup>/NADH Metabolism and NAD<sup>+</sup>-Dependent Enzymes in Cell Death and Ischemic Brain Injury: Current Advances and Therapeutic Implications
Current Medicinal Chemistry Adverse Effects of Statins - Mechanisms and Consequences
Current Drug Safety Pure Polyphenols Applications for Cardiac Health and Disease
Current Pharmaceutical Design 58-Year Old Men with Non-Stenotic Carotid Artery Plaques and the Relationship with Cardiovascular Risk Factors and Future Cardiovascular Events
Vascular Disease Prevention (Discontinued) Gender Differences in Autonomic Control of the Cardiovascular System
Current Pharmaceutical Design Anti-Hyperglycemic Agents for the Treatment of Type 2 Diabetes Mellitus: Role in Cardioprotection During the Last Decade
Endocrine, Metabolic & Immune Disorders - Drug Targets Responses Triggered by the Immune System in Hypertensive Conditions and Repercussions on Target Organ Damage: A Review
Current Cardiology Reviews Norlichexanthone Isolated from Fungus P16 Promotes the Secretion and Expression of Adiponectin in Cultured ST-13 Adipocytes
Medicinal Chemistry Is Atorvastatin Superior to Other Statins? Analysis of the Clinical Trials with Atorvastatin Having Cardiovascular Endpoints
Reviews on Recent Clinical Trials Diabetic Cardiomyopathy and Oxidative Stress: Role of Antioxidants
Cardiovascular & Hematological Agents in Medicinal Chemistry Circulating Biomarkers of Collagen Metabolism and Prognosis of Heart Failure with Reduced or Mid-Range Ejection Fraction
Current Pharmaceutical Design Diabetes and Heart Failure: Is it Hyperglycemia or Hyperinsulinemia?
Current Vascular Pharmacology Fetal Programming of the Human Brain: Is there a Link with Insurgence of Neurodegenerative Disorders in Adulthood?
Current Medicinal Chemistry Angiotensin II Type I Receptor Blocker and Endothelial Function in Humans: Role of Nitric Oxide and Oxidative Stress
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Enhanced Neuroprotection of Ischemic Stroke Based on Liposomal Drug Delivery System Loading a Novel Uncoupler of Ischemia-induced nNOSPSD- 95
Current Signal Transduction Therapy